Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Directors of Adamas Pharmaceuticals, Inc. (the Company) took the
following compensation actions with respect to the Companys Chief
Executive Officer and Chief Financial Officer (collectively, the
Officers).
January 1, 2017, and the bonuses for performance in 2016, as
follows:
|
Executive Officer
|
Title
|
Salary
|
2016 Bonus
|
|||
|
Gregory T. Went, Ph.D.
|
President and Chief Executive Officer
|
$517,500
|
$250,000
|
|||
|
William J. Dawson
|
Chief Financial Officer
|
$358,955
|
$104,955
|
referred to as RSUs, to the Officers to acquire the following
numbers of shares:
|
Executive Officer
|
Title
|
Stock Options
|
RSUs
|
|||
|
Gregory T. Went, Ph.D.
|
President and Chief Executive Officer
|
138,750
|
23,125
|
|||
|
William J. Dawson
|
Chief Financial Officer
|
45,000
|
7,500
|
the closing price of the Companys common stock on the date of
grant, and vest in equal monthly installments over four years.
The RSUs vest with respect to 25% on each of the first, second,
third, and fourth anniversaries of March 20, 2017.
About Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures). Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Recent Trading Information
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) closed its last trading session up +0.88 at 18.08 with 185,719 shares trading hands.
